DE3689620D1 - Durch cys-kodon modifizierte dns. - Google Patents

Durch cys-kodon modifizierte dns.

Info

Publication number
DE3689620D1
DE3689620D1 DE86907171T DE3689620T DE3689620D1 DE 3689620 D1 DE3689620 D1 DE 3689620D1 DE 86907171 T DE86907171 T DE 86907171T DE 3689620 T DE3689620 T DE 3689620T DE 3689620 D1 DE3689620 D1 DE 3689620D1
Authority
DE
Germany
Prior art keywords
dna modified
cys codon
dna sequence
exhibit
codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE86907171T
Other languages
English (en)
Other versions
DE3689620T2 (de
Inventor
Erfinder Wird Nachtraeglich Benannt Der
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOSPITAL BOSTON, University of
Original Assignee
HOSPITAL BOSTON, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOSPITAL BOSTON, University of filed Critical HOSPITAL BOSTON, University of
Application granted granted Critical
Publication of DE3689620D1 publication Critical patent/DE3689620D1/de
Publication of DE3689620T2 publication Critical patent/DE3689620T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE3689620T 1985-11-13 1986-11-13 Durch cys-kodon modifizierte dns. Expired - Lifetime DE3689620T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79816385A 1985-11-13 1985-11-13
PCT/US1986/002444 WO1987002987A1 (en) 1985-11-13 1986-11-13 Cys codon-modified dna

Publications (2)

Publication Number Publication Date
DE3689620D1 true DE3689620D1 (de) 1994-03-17
DE3689620T2 DE3689620T2 (de) 1994-06-16

Family

ID=25172688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3689620T Expired - Lifetime DE3689620T2 (de) 1985-11-13 1986-11-13 Durch cys-kodon modifizierte dns.

Country Status (6)

Country Link
EP (1) EP0246307B1 (de)
JP (1) JP2635035B2 (de)
AT (1) ATE101162T1 (de)
AU (1) AU6733287A (de)
DE (1) DE3689620T2 (de)
WO (1) WO1987002987A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5290914A (en) * 1988-04-28 1994-03-01 Mycogen Corporation Hybrid diphtheria-B.t. pesticidal toxins
IL93723A (en) * 1989-03-22 1997-02-18 Merck & Co Inc Cystein modified truncated pseudomonas exotoxin A
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5767072A (en) * 1989-09-14 1998-06-16 Board Of Regents, The University Of Texas System Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
ES2155821T5 (es) * 1990-03-02 2008-04-16 Boston Medical Center Corporation Toxinas quimericas mejoradas.
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
ATE433998T1 (de) 1997-03-05 2009-07-15 Us Health Divalent anti-t-zellen immuntoxinen und deren verwendung
CA2283497A1 (en) * 1997-03-05 1998-09-11 David M. Neville Vectors and methods for expression of mutant proteins
FR2827606A1 (fr) * 2001-07-20 2003-01-24 Pf Medicament Nouveaux derives d'anatoxines diphteriques et leur utilisation comme porteur

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX197183A (es) * 1982-05-05 1994-02-28 Genentech Inc Activador de plasminogeno de tejido humano
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US4468382A (en) * 1982-07-15 1984-08-28 New England Medical Center, Inc. Polypeptide-toxin hybrid protein

Also Published As

Publication number Publication date
EP0246307A1 (de) 1987-11-25
JP2635035B2 (ja) 1997-07-30
DE3689620T2 (de) 1994-06-16
AU6733287A (en) 1987-06-02
EP0246307B1 (de) 1994-02-02
WO1987002987A1 (en) 1987-05-21
JPS63501799A (ja) 1988-07-21
ATE101162T1 (de) 1994-02-15
EP0246307A4 (de) 1989-06-13

Similar Documents

Publication Publication Date Title
DE3689620D1 (de) Durch cys-kodon modifizierte dns.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
DE3586206D1 (de) Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
DE3686397D1 (de) Kovalent gebundene polypeptid enthaltende zellmodulatoren.
DK163319C (da) Ekstrusionsfast indretning til taetning mellem to ud for hinanden beliggende flader.
DE3667946D1 (de) Tisch zum fixieren am ruecken eines sessels.
DE3786943D1 (de) Gasdurchlaessige elektrode.
FI101720B1 (fi) Synteettisen DNA:n konstruointi ja sen käyttö suurten polypeptidien synteesissä
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
NO852016L (no) Spjeldventil.
FI872405A (fi) Sjaelvstaendig kylanordning foer livsmedelsbehaollare.
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DE3584494D1 (de) Druckgasschalter.
DE3578744D1 (de) Natriumarmes, als kochsalzsubstitut geeignetes salzgemisch.
ES2026206T3 (es) Procedimiento para mejorar la expresion de proteina de eucariota.
DE3671090D1 (de) Notausloesbares absperrventil.
BR9204788A (pt) Sequencia de dna,proteina,gene quimerico,vetor,celula transformada e planta transformada
FI971276A (fi) Lerk-6:ksi nimetty sytokiini
ES539738A0 (es) Un procedimiento de preparar una composicion quimica, marca-dora de material proteinico
EP0206200A3 (en) Human cholinesterase-type proteins and their production
DE3683133D1 (de) Dichter stellantrieb-zusammenbau.
NO841452L (no) Vendeventil.
ATE92961T1 (de) Dns-sequenz.
DE3583698D1 (de) Perkutaner absorptions-beschleuniger und diesen enthaltendes praeparat.
DK502585A (da) Stativ til forholdsvis tunge haandvaaben

Legal Events

Date Code Title Description
8364 No opposition during term of opposition